The price transparency movement in American healthcare carries a foundational assumption that has never been adequately tested: that revealing prices creates accountability. It is an assumption borrowed from competitive market theory and applied, with decreasing justification, to a sector characterized by insurance intermediation, oligopolistic market structures, severe information asymmetries, and a product that most consumers neither freely choose nor are equipped to evaluate. Transparency, in this environment, does something — but it may not be what the policy architects imagined.
The Accountability Gap
Accountability requires not just disclosure but consequence. A health system that publishes rates three times the Medicare rate and faces no regulatory sanction, no network exclusion, and no meaningful patient attrition has disclosed a fact without incurring any accountability. The disclosure itself becomes a form of regulatory compliance that satisfies the letter of the reform while leaving its animating logic unfulfilled. Patient Rights Advocate’s compliance reports have documented this pattern repeatedly: hospitals that publish data technically — in formats and at granularity levels that satisfy the rule’s minimum requirements but serve no analytical purpose — have perfected the performance of transparency without its substance.
Turquoise Health is an honest actor in this landscape — a company doing genuine technical work to make compliance data analytically useful. The critique here is not of the platform but of the policy framework it operates within, and of the broader political consensus that has treated disclosure as a reform strategy rather than as a precondition for reform. Disclosure without corresponding obligations — on pricing, on network inclusion, on rate justification — is a regulatory posture that satisfies reformers without inconveniencing incumbents.
Who Benefits From the Map
Consider who actually uses hospital price transparency data and to what effect. Sophisticated institutional actors — large self-insured employers, benefits consultants, private equity-backed analytics firms, and increasingly health systems themselves — have the resources and analytical capacity to extract value from rate data. Individual patients, who are the theoretical beneficiaries of the transparency movement, continue to face prices at the point of care that bear no reliable relationship to published rates; they are insulated from the negotiated rate by cost-sharing structures, network rules, and billing practices that transparency does not touch. The information has been democratized. Access to its benefits has not.
There is a subtler distortion worth naming. If dominant health systems use rate transparency platforms to benchmark against competitors, they gain the same intelligence that payers are using to pressure them — and they use it to set rate floors rather than ceilings. A system that discovers its neurosurgery rates are below the regional median does not typically lower other rates to compensate; it raises neurosurgery rates in the next contract cycle and defends the increase as market-justified. Price transparency, in this dynamic, becomes a coordination mechanism that supports rate convergence at elevated levels — not because of any explicit collusion, but because access to common information naturally produces common reference points.
The Substitution Effect in Policy
The most corrosive effect of the price transparency movement may be its substitution for more consequential interventions. Legislative energy that might have gone toward rate regulation, all-payer claims databases with mandatory public reporting, or antitrust enforcement against hospital mergers has been partially redirected toward disclosure mandates that are politically less controversial and operationally less threatening to the industry. Transparency is the reform that the industry can live with. That alone should prompt skepticism about how much structural change it can produce.
None of this forecloses the possibility that price transparency, accumulated over years and combined with other pressures, produces meaningful change. The Consolidated Appropriations Act of 2021 added transparency requirements for insurers and PBMs that extend the disclosure logic further up the supply chain, and the full effects of that expansion are still working through the system. But the baseline expectation — that publishing prices disciplines them — has not been validated in hospital markets after four years of compliance. At some point, the absence of evidence becomes evidence of the absence. That moment may be approaching faster than the transparency advocates are prepared to acknowledge.
